Literature DB >> 34157461

Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells.

Maria Y Liu1, John D Klement2, Candace J Langan3, Jan van Riggelen3, Kebin Liu4.   

Abstract

T lymphoma cells may constitutively express PD-1 and PD-L1. The relative role of PD-1 and PD-L1 in T lymphoma is incompletely understood. We report here that PD-1+ PDL-1+ human T lymphoma cells exhibit constitutive hyperactivation of the TCR signaling and do not respond to PD-L1-mediated suppression in vitro. Knocking out PD-1 or PD-L1 has no effects on T lymphoma cell apoptosis and proliferation in vitro, but significantly increased tumor-bearing mouse survival. Our findings determine that the constitutively active TCR signaling pathway maintain T lymphoma cell growth in vitro and that both PD-1 and PD-L1 promote T lymphoma growth in vivo.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PD-1; PD-L1; T cell receptor; T lymphoma

Mesh:

Substances:

Year:  2021        PMID: 34157461      PMCID: PMC8327398          DOI: 10.1016/j.cellimm.2021.104397

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.178


  19 in total

1.  NFATc1 regulates PD-1 expression upon T cell activation.

Authors:  Kenneth J Oestreich; Hyesuk Yoon; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Authors:  Owen A O'Connor; Steven Horwitz; Tamás Masszi; Achiel Van Hoof; Peter Brown; Jeannette Doorduijn; Georg Hess; Wojciech Jurczak; Poul Knoblauch; Shanta Chawla; Gajanan Bhat; Mi Rim Choi; Jan Walewski; Kerry Savage; Francine Foss; Lee F Allen; Andrei Shustov
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

3.  Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.

Authors:  Kanchan Kantekure; Yusong Yang; Puthiyaveettil Raghunath; Andras Schaffer; Anders Woetmann; Qian Zhang; Niels Odum; Mariusz Wasik
Journal:  Am J Dermatopathol       Date:  2012-02       Impact factor: 1.533

4.  Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1.

Authors:  Hui Li; Xiaoqiang Li; Shuang Liu; Lei Guo; Bo Zhang; Jubo Zhang; Qinghai Ye
Journal:  Hepatology       Date:  2017-12       Impact factor: 17.298

Review 5.  A three-signal model of T-cell lymphoma pathogenesis.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

Review 6.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 7.  T cell activation.

Authors:  Jennifer E Smith-Garvin; Gary A Koretzky; Martha S Jordan
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

8.  Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.

Authors:  Tatsunori Goto; Tetsuya Nishida; Erina Takagi; Kotaro Miyao; Daisuke Koyama; Reona Sakemura; Ryo Hanajiri; Keisuke Watanabe; Nobuhiko Imahashi; Seitaro Terakura; Makoto Murata; Hitoshi Kiyoi
Journal:  J Immunother       Date:  2016-10       Impact factor: 4.456

9.  FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.

Authors:  Yvette L Kasamon; R Angelo de Claro; Yaping Wang; Yuan Li Shen; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2017-04-24

10.  T-cell lymphoma secondary to checkpoint inhibitor therapy.

Authors:  Kartik Anand; Joe Ensor; Sai Ravi Pingali; Patrick Hwu; Madeleine Duvic; Stephen Chiang; Roberto Miranda; Youli Zu; Swaminathan Iyer
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.